Floatz logo

Givinostat

Becker Muscular Dystrophy

ItalfarmacoSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Becker Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
(-)-Epicatechin
Craig McDonald, MD
Phase 2BB
Carvedilol
Catholic University, Italy
Phase 4BB
Tadalafil
Cedars-Sinai Medical Center
Phase 4BB
Ataluren
PTC Therapeutics
Phase 3BB
Corpril
Catholic University, Italy
Phase 4B

View all 18 →

Same molecule, other indications

Givinostat is also rated in:

Duchenne muscular dystrophyActive
BB
Indicative · Phase 3
64 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative · Phase 1/2
49 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →